- Case report
- Open Access
- Open Peer Review
Disruption of AP3B1by a chromosome 5 inversion: a new disease mechanism in Hermansky-Pudlak syndrome type 2
© Jones et al.; licensee BioMed Central Ltd. 2013
- Received: 29 October 2012
- Accepted: 20 March 2013
- Published: 4 April 2013
Hermansky-Pudlak syndrome 2 (HPS2; OMIM #608233) is a rare, autosomal recessive disorder caused by loss-of-function genetic variations affecting AP3B1, which encodes the β3A subunit of the adaptor-related protein complex 3 (AP3). Phenotypic characteristics include reduced pigmentation, absent platelet dense granule secretion, neutropenia and reduced cytotoxic T lymphocyte (CTL) and natural killer (NK) cell function. To date HPS2 has been associated with non-synonymous, stop-gain or deletion-insertion nucleotide variations within the coding region of AP3B1.
We describe a consanguineous female infant with reduced pigmentation, neutropenia and recurrent infections. Platelets displayed reduced aggregation and absent ATP secretion in response to collagen and ADP, indicating a platelet dense granule defect. There was increased basal surface expression of CD107a (lysosome-associated membrane protein 1(LAMP-1)) on NK cells and CTLs from the study subject and a smaller increase in the percentage of CD107a positive cells after stimulation compared to most healthy controls. Immunoblotting of protein extracts from EBV-transformed lymphoblasts from the index case showed absent expression of full-length AP-3 β3A subunit protein, confirming a phenotypic diagnosis of HPS2.
The index case displayed a homozygous pericentric inv(5)(p15.1q14.1), which was also detected as a heterozygous defect in both parents of the index case. No loss of genetic material was demonstrated by microarray comparative genome hybridisation at 60kb resolution. Fluorescence in-situ hybridisation using the 189.6kb probe RP11-422I12, which maps to 5q14.1, demonstrated dual hybridisation to both 5q14.1 and 5p15.1 regions of the inverted Chr5. The RP11-422I12 probe maps from intron 1 to intron 16 of AP3B1, thus localising the 5q inversion breakpoint to within AP3B1. The probe RP11-211K15, which corresponds to an intergenic region on 5p also showed dual hybridisation, enabling localisation of the 5p inversion breakpoint.
This case report extends the phenotypic description of the very rare disorder HPS2. Our demonstration of a homozygous Chr5 inversion predicted to disrupt AP3B1 gene provides a novel pathogenic mechanism for this disorder.
- Chromosome 5 inversion
- Hermansky-Pudlak syndrome type 2
- Adaptor-related protein complex 3 β3A subunit
- Fluorescence in situ hybridisation
Hermansky-Pudlak syndrome (HPS) is a group of genetically heterogeneous disorders that are caused by mutations in genes that affect the synthesis and function of lysosome-related organelles (LRO) [1, 2]. LRO are specialised structures that have the ultra-structural and functional characteristics of lysosomes but serve as secretory granules in some cell types. They are widely distributed in haematopoietic and other tissues and include melanosomes in melanocytes, dense granules in platelets, lamellar bodies in alveolar type II epithelial cells, azurophilic granules in neutrophils and lytic granules in cytotoxic T lymphocytes (CTL) and natural killer (NK) cells . In keeping with the distribution of LRO, abnormal LRO synthesis or function in HPS manifests as a complex multi-organ phenotype. Features common to all HPS sub-types include reduced pigmentation caused by absence of melanosomes and a mild bleeding diathesis caused by absence of platelet dense granules. Other phenotype features differ according to HPS subtype but may include respiratory fibrosis, colitis and immunodeficiency [1, 2].
HPS type 2 (HPS2) is a very rare subtype of HPS in which reduced pigmentation and platelet dysfunction are accompanied by neutropenia [4–13] and in some cases, reduced CTL and NK cell cytotoxicity. This may manifest as increased susceptibility to viral infection and rarely, haemophagocytic lymphohistiocytosis (HLH) in response to viral infection [7, 8, 12]. HPS2 has previously been associated with loss-of-function nucleotide variations in AP3B1 that encodes the β3A-subunit of the adaptor protein complex 3 (AP-3) . AP-3 is essential for trafficking cargo proteins to LRO. Consequently, proteins such as CD63 and LAMP-1, which are normally targeted to the lysosome compartment in haematopoietic cells, are incorrectly trafficked to the cell surface and accumulate in endosomes . In all the previous reports of HPS2, loss of AP-3 β3A-subunit expression is associated with missense, nonsense or deletion-insertion nucleotide variations within AP3B1. Here we report the clinical and laboratory phenotype of a new index case with HPS2 associated with a homozygous pericentric inversion of Chr5. We demonstrate that the 5q inversion breakpoint lies within AP3B1 thus providing a new mechanistic explanation for the HPS2 phenotype.
Laboratory investigations revealed that P1 had persistent neutropenia (typically 0.2 × 109/l; reference interval 1.5-7.0 × 109/l), with normal neutrophil morphology in peripheral blood. Serum concentrations of immunoglobulin subclasses were normal and there were satisfactory antibody responses to childhood immunisations for haemophilus, tetanus and the 7-valent pneumococcal antigen suggesting normal B-lymphocyte function. Platelet impedance aggregation and secretion responses were monitored simultaneously using a CHRONO-LOG model 700 lumiaggregometer. Platelets from P1 displayed partial aggregation to 5 μg/ml collagen (maximum aggregation (MA) MA 14 Ω) and to 10 μM ADP (MA 9 Ω) whereas these agonists induced full aggregation of control platelets (MA 21 Ω and 24 Ω with 5 μg/ml collagen 10 μM ADP respectively; Figure 1C). There was brisk ATP secretion from control platelets in response to 5 μg/ml collagen and to10 μM ADP (2.34 nmol and 1.06 nmol ATP respectively). However, platelet ATP secretion was absent in P1 when stimulated with these agonists, indicating defective platelet dense granule release (Figure 1C).
A FACS-based granule release assay (GRA), using the surface expression of CD107a (lysosome-associated membrane protein 1 (LAMP-1)) as a marker of lytic granule exocytosis, was used to assess CTL and NK cells in a resting state, and after stimulation with anti-CD3 or phytohaemagglutinin respectively [14, 15]. Granule secretion was determined by measuring the increase in the percentage of CD107a positive cells, determined from 100,000 events, in the resting state versus activated state. The percentage of CD107a positive NK cells in the resting state was higher in P1 (5.4%) compared to a healthy control (HC) measured in parallel (0.9%; Additional file 1: Figure S1). After cell stimulation, the proportion of CD107a positive CTL and NK cells from P1 increased by 0.8% and 5.5% respectively. These responses were within the lowest quartile of the 95% reference interval of responses determined at our laboratory by testing 39 healthy controls (Figure 1D).
As this clinical and laboratory phenotype was consistent with HPS2, immunoblots were performed to determine the expression level of the AP3 β3A-subunit in EBV-immortalised B lymphoblastoid cells from P1 (Prepared by the Health Protection Agency Culture Collections, Salisbury, UK). Cell lysates were resolved by electrophoresis on a sodium dodecyl sulphate-polyacrylamide gel (SDS-PAGE) and were immunoblotted with a rabbit polyclonal anti-β3A antibody (a gift from Professor Margaret Robinson, University of Cambridge) and a control rabbit polyclonal anti-GAPDH (Santa Cruz). In positive control cell lysates prepared from fresh healthy donor lymphocytes, immunoblotting demonstrated a single protein band of approximate molecular weight 123 kDa that is the expected molecular weight of the AP3 β3A-subunit. In contrast, there was no detectible full length AP3 β3A-subunit in lymphoblastoid cells from P1, or in a negative control lymphoblastoid cell lysates obtained from a previously reported patient with HPS2  (Figure 1E).
AP3B1, which encodes the AP-3 β3A-subunit, lies at cytoband 5q14.1 in the region of the initially estimated 5q inversion breakpoint. Therefore, we used fluorescence in-situ hybridisation (FISH) using probes prepared from the Sanger 30 kb EnsEMBL clone set to fine map both inversion breakpoints in metaphases prepared from P2, who displayed both normal and inverted Chr5. The hybridisation signal from the probe RP11-317N14 (NCBI 36 nomenclature), which maps telomeric from AP3B1 intron (i) 6 to include exons (e)1-6 and the 5’ flanking sequence correctly localised to q14.1 of the inverted Chr5. However, hybridisation signals from probe RP11-59M8 (AP3B1 i7 to i22), and probe RP11-51E14 (centromeric from AP3B1 i17 to include e18-e26 and the 3′- flanking sequence) localized to 5p similar to the inv(5)(p15.1q13.3) observed in the initial diagnostic karyotype. Together, these observations suggested that the 5q breakpoint lay within AP3B1. This was confirmed by the detection of hybridisation signal from RP11-422I12 (AP3B1 i1 to i16 (Chr5:77417815–77569358)) at both q14.1 and p15.1 of the inverted Chr5 but only at 5q in the normal Chr5 (Figure 2B and 2D).
The 5p inversion breakpoint was mapped using a similar strategy. In this analysis, the probe RP11-211K15, which maps to Chr5:18263045–18430126 within 5p15.1 displayed dual hybridisation to both the cytobands 5p15.1 and 15q14.1, consistent with the karyotype findings. RP11-211K15 maps to a genomic region on 5p that contains no identifiable genes in the RefSeq, UCSC or GENCODE databases (Figure 2B and 2C).
We describe a new index case with reduced pigmentation and a platelet dense granule defect indicating an HPS group disorder. In addition, there was a clinical immunodeficiency phenotype, a persistent neutropenia and radiographic evidence suggestive of early pulmonary fibrosis. This phenotype was indicative of HPS2, which we confirmed by showing absent expression of AP-3 β3A subunit in lymphocytes by immunoblotting. It is noteworthy that the index case also displayed increased surface expression of lytic granule markers in resting CTL and NK cells and diminished granule release consistent with mis-trafficking of lytic granules. This is similar to, but less marked than in other secretopathies such as Chediak Higashi syndrome (OMIM #214500), Griscelli syndrome (OMIM #607624), and Familial haemophagocytic lymphohistiocytosis disorders (OMIM #608898 and #613101), which may be complicated by episodes of haemophagocytic syndrome in response to viral infection [16–18]. This is in keeping with other clinical descriptions of HPS2 in which haemophagocytic syndrome has been reported in only a minority of cases [7, 8, 12].
To date, the molecular pathogenesis of HPS2 has been reported in only 13 index cases. In these individuals, a total of 14 nucleotide variations within AP3B1 have been identified, in all cases occurring as homozygous or compound heterozygous traits. These include 5 short deletion variations [10, 12, 19]; 3 nonsense single nucleotide variations (SNV) [7, 9]; 2 insertions [8, 20]; 2 splice site SNV [20, 21]; 1 missense SNV  and 1 complex deletion-insertion , all of which are predicted to prevent expression of the AP-3 β3A subunit. Our finding that a previously unreported homozygous pericentric inversion (inv(5)(p15.1q14.1) was also associated with the HPS2 phenotype extends the repertoire of genetic variations associated with this disorder. We also demonstrated that the FISH probe RP11-422I12 hybridised to both the cytobands 5q14.1 and 5p15.1 thus localising the inversion breakpoint to within the boundaries of this probe. Since RP11-422I12 maps to AP3B1 intron 1 to intron 16, the inversion necessarily lies within AP3B1 and is predicted to disrupt gene expression. We cannot rule out the possibility of loss of genetic material within these boundaries in AP3B1 related to the inversion. However, the array cGH data indicate that if any deletion occurred it is likely to be at less than 60kb size. Since we also mapped the 5p inversion breakpoint to a region of 5p15.1 that contained no CCDS-annotated genes, it is likely that the phenotype of the index case arose only from disruption of AP3B1 at the 5q inversion breakpoint. This represents a novel molecular mechanism for HPS2.
Written informed consent was obtained from the mother of the index case for publication of this case report and any accompanying images. A copy of the written consent is available for review by the series editor of this journal. Laboratory investigations were performed after approval from the UK NHS National Research Ethics Service (07/Q0704/48).
Professor Margaret Robinson (University of Cambridge) for gift of anti-β3A antibody.
MLJ is funded through BHF programme RG/09/007/27917 (Genotyping and Platelet Phenotyping study (http://www.birmingham.ac.uk/plateletgap)).
- Wei ML: Hermansky-Pudlak syndrome: a disease of protein trafficking and organelle function. Pigment Cell Res. 2006, 19 (1): 19-42. 10.1111/j.1600-0749.2005.00289.x.View ArticlePubMedGoogle Scholar
- Wei AH, Li W: Hermansky-Pudlak syndrome: pigmentary and non-pigmentary defects and their pathogenesis. Pigment Cell Melanoma Res. 2012, 26: 176-192.View ArticlePubMedGoogle Scholar
- Raposo G, Marks MS, Cutler DF: Lysosome-related organelles: driving post-Golgi compartments into specialisation. Curr Opin Cell Biol. 2007, 19 (4): 394-401. 10.1016/j.ceb.2007.05.001.View ArticlePubMedPubMed CentralGoogle Scholar
- Badolato R, Parolini S: Novel insights from adaptor protein 3 complex deficiency. J Allergy Clin Immunol. 2007, 120 (4): 735-741. 10.1016/j.jaci.2007.08.039. quiz 742–733View ArticlePubMedGoogle Scholar
- Chiang PW, Oiso N, Gautam R, Suzuki T, Swank RT, Spritz RA: The Hermansky-Pudlak syndrome 1 (HPS1) and HPS4 proteins are components of two complexes, BLOC-3 and BLOC-4, involved in the biogenesis of lysosome-related organelles. J Biol Chem. 2003, 278 (22): 20332-20337. 10.1074/jbc.M300090200.View ArticlePubMedGoogle Scholar
- Clark R, Griffiths GM: Lytic granules, secretory lysosomes and disease. Curr Opin Immunol. 2003, 15 (5): 516-521. 10.1016/S0952-7915(03)00113-4.View ArticlePubMedGoogle Scholar
- Enders A, Zieger B, Schwarz K, Yoshimi A, Speckmann C, Knoepfle EM, Kontny U, Muller C, Nurden A, Rohr J: Lethal hemophagocytic lymphohistiocytosis in Hermansky-Pudlak syndrome type II. Blood. 2006, 108 (1): 81-87. 10.1182/blood-2005-11-4413.View ArticlePubMedGoogle Scholar
- Fontana S, Parolini S, Vermi W, Booth S, Gallo F, Donini M, Benassi M, Gentili F, Ferrari D, Notarangelo LD: Innate immunity defects in Hermansky-Pudlak type 2 syndrome. Blood. 2006, 107 (12): 4857-4864. 10.1182/blood-2005-11-4398.View ArticlePubMedGoogle Scholar
- Huizing M, Scher CD, Strovel E, Fitzpatrick DL, Hartnell LM, Anikster Y, Gahl WA: Nonsense mutations in ADTB3A cause complete deficiency of the beta3A subunit of adaptor complex-3 and severe Hermansky-Pudlak syndrome type 2. Pediatr Res. 2002, 51 (2): 150-158. 10.1203/00006450-200202000-00006.View ArticlePubMedGoogle Scholar
- Jung J, Bohn G, Allroth A, Boztug K, Brandes G, Sandrock I, Schaffer AA, Rathinam C, Kollner I, Beger C: Identification of a homozygous deletion in the AP3B1 gene causing Hermansky-Pudlak syndrome, type 2. Blood. 2006, 108 (1): 362-369. 10.1182/blood-2005-11-4377.View ArticlePubMedPubMed CentralGoogle Scholar
- Shotelersuk V, Dell’Angelica EC, Hartnell L, Bonifacino JS, Gahl WA: A new variant of Hermansky-Pudlak syndrome due to mutations in a gene responsible for vesicle formation. Am J Med. 2000, 108 (5): 423-427. 10.1016/S0002-9343(99)00436-2.View ArticlePubMedGoogle Scholar
- Wenham M, Grieve S, Cummins M, Jones ML, Booth S, Kilner R, Ancliff PJ, Griffiths GM, Mumford AD: Two patients with Hermansky Pudlak syndrome type 2 and novel mutations in AP3B1. Haematologica. 2010, 95 (2): 333-337. 10.3324/haematol.2009.012286.View ArticlePubMedGoogle Scholar
- Kurnik K, Bartsch I, Maul-Pavicic A, Ehl S, Sandrock-Lang K, Bidlingmaier C, Rombach N, Busse A, Belohradsky BH, Muller-Hocker J: Novel mutation in Hermansky-Pudlak syndrome type 2 with mild immunological phenotype. Platelets. 2012, 10.3109/09537104.2012.741275.Google Scholar
- Wheeler RD, Cale CM, Cetica V, Arico M, Gilmour KC: A novel assay for investigation of suspected familial haemophagocytic lymphohistiocytosis. Br J Haematol. 2010, 150 (6): 727-730. 10.1111/j.1365-2141.2010.08289.x.View ArticlePubMedGoogle Scholar
- Cetica V, Santoro A, Gilmour KC, Sieni E, Beutel K, Pende D, Marcenaro S, Koch F, Grieve S, Wheeler R: STXBP2 mutations in children with familial haemophagocytic lymphohistiocytosis type 5. J Med Genet. 2010, 47 (9): 595-600. 10.1136/jmg.2009.075341.View ArticlePubMedPubMed CentralGoogle Scholar
- Gholam C, Grigoriadou S, Gilmour KC, Gaspar HB: Familial haemophagocytic lymphohistiocytosis: advances in the genetic basis, diagnosis and management. Clin Exp Immunol. 2011, 163 (3): 271-283. 10.1111/j.1365-2249.2010.04302.x.View ArticlePubMedPubMed CentralGoogle Scholar
- Jessen B, Maul-Pavicic A, Ufheil H, Vraetz T, Enders A, Lehmberg K, Langler A, Gross-Wieltsch U, Bay A, Kaya Z: Subtle differences in CTL cytotoxicity determine susceptibility to hemophagocytic lymphohistiocytosis in mice and humans with Chediak-Higashi syndrome. Blood. 2011, 118 (17): 4620-4629. 10.1182/blood-2011-05-356113.View ArticlePubMedGoogle Scholar
- Menasche G, Pastural E, Feldmann J, Certain S, Ersoy F, Dupuis S, Wulffraat N, Bianchi D, Fischer A, Le Deist F: Mutations in RAB27A cause Griscelli syndrome associated with haemophagocytic syndrome. Nat Genet. 2000, 25 (2): 173-176. 10.1038/76024.View ArticlePubMedGoogle Scholar
- Shotelersuk V, Hazelwood S, Larson D, Iwata F, Kaiser-Kupfer MI, Kuehl E, Bernardini I, Gahl WA: Three new mutations in a gene causing Hermansky-Pudlak syndrome: clinical correlations. Mol Genet Metab. 1998, 64 (2): 99-107. 10.1006/mgme.1998.2679.View ArticlePubMedGoogle Scholar
- Clark RH, Stinchcombe JC, Day A, Blott E, Booth S, Bossi G, Hamblin T, Davies EG, Griffiths GM: Adaptor protein 3-dependent microtubule-mediated movement of lytic granules to the immunological synapse. Nat Immunol. 2003, 4 (11): 1111-1120. 10.1038/ni1000.View ArticlePubMedGoogle Scholar
- Chiang PW, Spector E, Thomas M, Frei-Jones M: Novel mutation causing Hermansky-Pudlak Syndrome Type 2. Pediatr Blood Cancer. 2010, 55 (7): 1438-10.1002/pbc.22793.View ArticlePubMedGoogle Scholar
- The pre-publication history for this paper can be accessed here:http://www.biomedcentral.com/1471-2350/14/42/prepub
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.